Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Up 336.3% in June

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 1,511,367 shares, a growth of 336.3% from the June 15th total of 346,372 shares. Based on an average daily volume of 376,254 shares, the days-to-cover ratio is currently 4.0 days. Currently, 0.7% of the company’s shares are sold short.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its position in shares of Enlivex Therapeutics by 99.4% during the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after acquiring an additional 156,336 shares in the last quarter. HRT Financial LP boosted its holdings in Enlivex Therapeutics by 719.4% in the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after purchasing an additional 135,198 shares during the period. Jane Street Group LLC boosted its holdings in Enlivex Therapeutics by 527.4% in the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after purchasing an additional 67,886 shares during the period. Invesco Ltd. bought a new stake in Enlivex Therapeutics during the fourth quarter valued at $43,000. Finally, Susquehanna International Group LLP bought a new stake in Enlivex Therapeutics during the third quarter valued at $57,000. Institutional investors own 1.02% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. HC Wainwright lifted their target price on shares of Enlivex Therapeutics from $195.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, April 7th. Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Enlivex Therapeutics currently has a consensus rating of “Hold” and an average price target of $247.50.

Enlivex Therapeutics Stock Down 2.8%

Shares of ENLV traded down $0.19 during midday trading on Monday, hitting $6.67. The company had a trading volume of 99,417 shares, compared to its average volume of 31,371. The stock has a market cap of $112.32 million, a price-to-earnings ratio of -0.81 and a beta of 1.52. The company’s 50 day moving average price is $10.04 and its 200 day moving average price is $13.15. Enlivex Therapeutics has a 52 week low of $6.42 and a 52 week high of $31.50.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.